Antidiabetic therapy effects on bone metabolism and fracture risk (Q38078009)

28 August 2017

1 reference

title

Antidiabetic therapy effects on bone metabolism and fracture risk (English)

1 reference

28 August 2017

1 reference

A Montagnani

1

1 reference

PubMed ID

23368527

28 August 2017

S Gonnelli

series ordinal

2

1 reference

28 August 2017

24 February 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

9

1 reference

28 August 2017

784-791

1 reference

Impact of hip and vertebral fractures on quality-adjusted life years.

28 August 2017

1 reference

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

21 January 2018

1 reference

Osteoporosis and risk of fracture in patients with diabetes: an update

21 January 2018

1 reference

An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus.

21 January 2018

1 reference

Bone mass in young patients with type I diabetes

21 January 2018

1 reference

Bone mineral density and bone metabolism in diabetes mellitus

21 January 2018

1 reference

Young women with type 1 diabetes have lower bone mineral density that persists over time

21 January 2018

1 reference

Diabetes and risk of fracture: The Blue Mountains Eye Study

21 January 2018

1 reference

Older women with diabetes have an increased risk of fracture: a prospective study

21 January 2018

1 reference

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis

21 January 2018

1 reference

Older women with diabetes have a higher risk of falls: a prospective study

21 January 2018

1 reference

Skeletal involvement in patients with diabetes mellitus.

21 January 2018

1 reference

Endocrine regulation of energy metabolism by the skeleton

21 January 2018

1 reference

Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice

21 January 2018

1 reference

Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus

21 January 2018

1 reference

Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus.

21 January 2018

1 reference

Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men

21 January 2018

1 reference

The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training.

21 January 2018

1 reference

Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level.

21 January 2018

1 reference

Undercarboxylated osteocalcin is positively associated with free testosterone in male patients with type 2 diabetes mellitus

21 January 2018

1 reference

LRP6 mutation in a family with early coronary disease and metabolic risk factors

21 January 2018

1 reference

Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism

21 January 2018

1 reference

Which way does the Wnt blow? Exploring the duality of canonical Wnt signaling on cellular aging.

21 January 2018

1 reference

The WNT signalling pathway and diabetes mellitus

21 January 2018

1 reference

Bone formation is impaired in a model of type 1 diabetes.

21 January 2018

1 reference

Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients

21 January 2018

1 reference

Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links

21 January 2018

1 reference

21 January 2018

1 reference

Pentosidine effects on human osteoblasts in vitro.

21 January 2018

1 reference

The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs

21 January 2018

1 reference

Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia

21 January 2018

1 reference

Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes

21 January 2018

1 reference

PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors

21 January 2018

1 reference

Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms

21 January 2018

1 reference

Improving metabolic control reverses the histomorphometric and biomechanical abnormalities of an experimentally induced bone defect in spontaneously diabetic rats

21 January 2018

1 reference

Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes

21 January 2018

1 reference

Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial

21 January 2018

1 reference

Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study

21 January 2018

1 reference

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

21 January 2018

1 reference

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study

21 January 2018

1 reference

Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture

21 January 2018

1 reference

Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

21 January 2018

1 reference

Unraveling the mechanism of action of thiazolidinediones

21 January 2018

1 reference

Multilineage potential of adult human mesenchymal stem cells

21 January 2018

1 reference

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo

21 January 2018

1 reference

Rosiglitazone RECORD study: glucose control outcomes at 18 months

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production

21 January 2018

1 reference

The mode of action of thiazolidinediones

21 January 2018

1 reference

Pluripotency of mesenchymal stem cells derived from adult marrow

21 January 2018

1 reference

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

21 January 2018

1 reference

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

21 January 2018

1 reference

Potential role of pancreatic and enteric hormones in regulating bone turnover.

21 January 2018

1 reference

Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors

21 January 2018

1 reference

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

21 January 2018

1 reference

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

21 January 2018

1 reference

Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.

21 January 2018

1 reference

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice

21 January 2018

1 reference

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

Role of advanced glycation end products (AGEs) in osteoporosis in diabetes

21 January 2018

1 reference

Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes

21 January 2018

1 reference

Bone Density in Non-Insulin-Dependent Diabetes Mellitus: The Rotterdam Study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12077

1 reference

28 August 2017

1 reference

PubMed ID

23368527